Literature DB >> 23552369

Cell-based therapeutics: the next pillar of medicine.

Michael A Fischbach1, Jeffrey A Bluestone, Wendell A Lim.   

Abstract

Two decades ago, the pharmaceutical industry-long dominated by small-molecule drugs-was revolutionized by the the advent of biologics. Today, biomedicine sits on the cusp of a new revolution: the use of microbial and human cells as versatile therapeutic engines. Here, we discuss the promise of this "third pillar" of therapeutics in the context of current scientific, regulatory, economic, and perceptual challenges. History suggests that the advent of cellular medicines will require the development of a foundational cellular engineering science that provides a systematic framework for safely and predictably altering and regulating cellular behaviors.

Entities:  

Mesh:

Year:  2013        PMID: 23552369      PMCID: PMC3772767          DOI: 10.1126/scitranslmed.3005568

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  27 in total

1.  Advancing stem cell biology toward stem cell therapeutics.

Authors:  David Scadden; Alok Srivastava
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

2.  Community health care: therapeutic opportunities in the human microbiome.

Authors:  Justin L Sonnenburg; Michael A Fischbach
Journal:  Sci Transl Med       Date:  2011-04-13       Impact factor: 17.956

3.  Cell therapy industry: billion dollar global business with unlimited potential.

Authors:  Chris Mason; David A Brindley; Emily J Culme-Seymour; Natasha L Davie
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

4.  A decade of cell therapy clinical trials (2000-2010).

Authors:  Emily J Culme-Seymour; Natasha L Davie; David A Brindley; Simon Edwards-Parton; Chris Mason
Journal:  Regen Med       Date:  2012-07       Impact factor: 3.806

Review 5.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 6.  Pluripotent stem cell-based cancer therapy: promise and challenges.

Authors:  Saul J Sharkis; Richard J Jones; Curt Civin; Yoon-Young Jang
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

7.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

8.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

9.  Synthetic gene networks that count.

Authors:  Ari E Friedland; Timothy K Lu; Xiao Wang; David Shi; George Church; James J Collins
Journal:  Science       Date:  2009-05-29       Impact factor: 47.728

10.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

View more
  126 in total

1.  Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance.

Authors:  Suzanne T Ildstad; Joseph Leventhal; Yujie Wen; Esma Yolcu
Journal:  Chimerism       Date:  2016-01-08

2.  Photothermal enhancement of chemotherapy mediated by gold-silica nanoshell-loaded macrophages: in vitro squamous cell carcinoma study.

Authors:  Steen J Madsen; En-Chung Shih; Qian Peng; Catherine Christie; Tatiana Krasieva; Henry Hirschberg
Journal:  J Biomed Opt       Date:  2016-01       Impact factor: 3.170

Review 3.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 4.  Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Authors:  Michael A Matthay; Piero Anversa; Jahar Bhattacharya; Bruce K Burnett; Harold A Chapman; Joshua M Hare; Derek J Hei; Andrew M Hoffman; Stella Kourembanas; David H McKenna; Luis A Ortiz; Harald C Ott; William Tente; Bernard Thébaud; Bruce C Trapnell; Daniel J Weiss; Jason X-J Yuan; Carol J Blaisdell
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

5.  A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.

Authors:  Andrea Pavesi; Anthony T Tan; Sarene Koh; Adeline Chia; Marta Colombo; Emanuele Antonecchia; Carlo Miccolis; Erica Ceccarello; Giulia Adriani; Manuela T Raimondi; Roger D Kamm; Antonio Bertoletti
Journal:  JCI Insight       Date:  2017-06-15

6.  A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.

Authors:  Shuai Xue; Jianli Yin; Jiawei Shao; Yuanhuan Yu; Linfeng Yang; Yidan Wang; Mingqi Xie; Martin Fussenegger; Haifeng Ye
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

7.  Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function.

Authors:  Claire E Repellin; Priya Ganesan; Javier F Alcudia; Haritha K Duggireddy Lakshmireddy; Puja Patel; Lucia Beviglia; Harold S Javitz; Lidia Sambucetti; Parijat Bhatnagar
Journal:  Adv Biosyst       Date:  2019-11-29

Review 8.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

9.  Tunable Expression Tools Enable Single-Cell Strain Distinction in the Gut Microbiome.

Authors:  Weston R Whitaker; Elizabeth Stanley Shepherd; Justin L Sonnenburg
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

Review 10.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.